Skip to main content
Bristol Myers SquibbFacility expansion

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

Source: Autobound Signal API · 117 signals tracked for Bristol Myers Squibb · updated

Get Bristol Myers Squibb's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bristol Myers Squibb this week? Use Autobound signals for bms.com.

What happened

Bristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing campus in Texas.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Pfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former. Over the last eight quarters, Pfizer experienced fluctuating quarter-over-quarter results with multiple periods of year-over-year contraction, whereas Bristol Myers Squibb maintained a steadier trajectory characterized by continuous year-over-year growth. Investors should watch whether Pfizer's recent return to positive year-over-year revenue growth stabilizes in upcoming quarters, or if the two companies see their absolute revenue gap continue to narrow. Motley Fool Issues Rare "Total Conviction" Buy Alert › Bristol Myers Squibb (NYSE:BMY) primarily generates revenue by developing and selling prescription medicines for oncology, immunology, and cardiovascular diseases. It recently received accelerated FDA approval for its multiple myeloma treatment Zenbexus, and it announced a $2.3 billion investment to build a new manufacturing campus in Texas. Pfizer (NYSE:PFE) primarily generates revenue by manufacturing and distributing a broad portfolio of prescription medicines and vaccines worldwide. It secured FDA approval for a Tukysa regimen to treat metastatic breast cancer, while it also received authorization for its updated seasonal COVID-19 vaccine for the upcoming season. Revenue here...

Keep reading with a free account

The rest of this article, and every signal for Bristol Myers Squibb, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Facility expansion

What this signalsA bigger facility often needs new equipment, systems and services.

Location
Texas, United States

More facility expansion signals at other companies

The full record

From the Signal API record

Details

Ticker
NYSE:BMY

Extraction

Confidence
85%
Detected
Oct 22, 2026
signal_type
news
signal_subtype
expands_facilities

Use this data

Get every facility expansion signal for Bristol Myers Squibb and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bristol Myers Squibb this week?”

  2. Send it to your own tools

    The Signal API returns facility expansion signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/9fc1697c-efcc-53bb-c109-05b7e8c82b9e returns this record as JSON. POST /v1/companies/enrich returns every signal for bms.com.

{
  "signal_id": "9fc1697c-efcc-53bb-c109-05b7e8c82b9e",
  "signal_type": "news",
  "signal_subtype": "expands_facilities",
  "detected_at": "2026-10-22T21:45:02+00:00",
  "company": {
    "name": "Bristol Myers Squibb",
    "domain": "bms.com"
  },
  "data": {
    "url": "https://www.aol.com/articles/bristol-myers-squibb-vs-pfizer-214502000.html",
    "title": "Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue - AOL.com",
    "ticker": "NYSE:BMY",
    "excerpt": "Pfizer currently generates a higher volume of absolute revenue, while Bristol Myers Squibb displays a more consistent baseline without the recent negative fluctuations seen by the former. Over the last eight quarters, Pfizer experienced fluctuating quarter-over-quarter results with multiple periods of year-over-year contraction, whereas Bristol Myers Squibb maintained a steadier trajectory characterized by continuous year-over-year growth. Investors should watch whether Pfizer's recent return to positive year-over-year revenue growth stabilizes in upcoming quarters, or if the two companies see their absolute revenue gap continue to narrow. Motley Fool Issues Rare \"Total Conviction\" Buy Alert › Bristol Myers Squibb (NYSE:BMY) primarily generates revenue by developing and selling prescription medicines for oncology, immunology, and cardiovascular diseases. It recently received accelerated FDA approval for its multiple myeloma treatment Zenbexus, and it announced a $2.3 billion investment to build a new manufacturing campus in Texas. Pfizer (NYSE:PFE) primarily generates revenue by manufacturing and distributing a broad portfolio of prescription medicines and vaccines worldwide. It secured FDA approval for a Tukysa regimen to treat metastatic breast cancer, while it also received authorization for its updated seasonal COVID-19 vaccine for the upcoming season. Revenue here refers...",
    "summary": "Bristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing campus in Texas.",
    "location": "Texas, United States",
    "planning": true,
    "image_url": "https://hermes.media.transform.aol.com/fd5d231a527ffec44ee88adb0810fbfff284a575/w_1200,c_scale,f_auto,q_auto/https://hermes.media.static.aol.com/media/2026/10/22/01d98240-8b58-3463-a299-fe383c651a2a/f1851268-da08-442b-995e-c1f42994ec9a.jpg",
    "confidence": 0.85,
    "published_at": "2026-10-22T21:45:02Z",
    "location_data": [
      {
        "state": "Texas",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "It recently received accelerated FDA approval for its multiple myeloma treatment Zenbexus, and it announced a $2.3 billion investment to build a new manufacturing campus in Texas."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.